ESTRO 2025 - Abstract Book

S450

Clinical - Breast

ESTRO 2025

Conclusion: Radiomic features and their changes from longitudinal ADC images offer additional predictive value for treatment response and exhibit unique correlations with breast tumor functional pathways, distinct from established prognostic factors.

Keywords: tumor response tracking, radiomic biomarkers

References: [1] Newitt, D. C., Partridge, S. C., Zhang, Z., Gibbs, J., Chenevert, T., Rosen, M., Bolan, P., Marques, H., Romanoff, J., Cimino, L., Joe, B. N., Umphrey, H., Ojeda-Fournier, H., Dogan, B., Oh, K. Y., Abe, H., Drukteinis, J., Esserman, L. J., & Hylton, N. M. (2021). ACRIN 6698/I-SPY2 Breast DWI [Data set]. The Cancer Imaging Archive. https://doi.org/10.7937/tcia.kk02-6d95 [2] Partridge, Savannah C., et al. "Diffusion-weighted MRI findings predict pathologic response in neoadjuvant treatment of breast cancer: the ACRIN 6698 multicenter trial." Radiology 289.3 (2018): 618-627. [3] Liberzon, Arthur, et al. "The molecular signatures database hallmark gene set collection." Cell systems 1.6 (2015): 417-425.